1.545

3.46% -0.045

Atai Life Sciences N V (ATAI)

Overview News Price History Option Chain Financials Discussions Forecast

Atai Life Sciences N V stock is traded at $1.545, with a volume of 266.99K. It is down -3.46% in the last 24 hours and up +27.92% over the past month. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Previous Close:

$1.59

Open:

$1.59

24h Volume:

266.99K

Relative Volume:

0.26

Market Cap:

$272.67M

Revenue:

$314.00K

Net Income/Loss:

$-40.23M

P/E Ratio:

-1.6793

EPS:

-0.92

Net Cash Flow:

$-84.71M

1W Performance:

+12.04%

1M Performance:

+27.92%

6M Performance:

-8.63%

1Y Performance:

+43.46%

1-Day Range:

$1.525

$1.60

1-Week Range:

$1.43

$1.95

52-Week Range:

$1.025

$2.85

Atai Life Sciences N V Stock (ATAI) Company Profile

Name

Atai Life Sciences N V

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

49 89 2153 9035

Address

WALLSTRASSE 16, BERLIN

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ATAI's Discussions on Twitter

Compare ATAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATAI	1.54	272.67M	314.00K	-40.23M	-84.71M	-0.92
VRTX	447.03	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.05	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	587.61	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.22	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.84	24.49B	3.30B	-501.07M	1.03B	11.54

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-01-22	Initiated	Loop Capital	Buy
Nov-30-21	Initiated	Maxim Group	Buy
Nov-11-21	Initiated	ROTH Capital	Buy
Oct-18-21	Initiated	H.C. Wainwright	Buy
Sep-01-21	Initiated	Jefferies	Buy
Jul-13-21	Initiated	Berenberg	Buy
Jul-13-21	Initiated	Canaccord Genuity	Buy
Jul-13-21	Initiated	Cantor Fitzgerald	Buy
Jul-13-21	Initiated	Citigroup	Buy
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Credit Suisse	Outperform
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform
Jul-08-21	Initiated	Aegis Capital	Buy

View All

Atai Life Sciences N V Stock (ATAI) Latest News

Nov 19, 2024

Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com

Nov 19, 2024

Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St

Nov 19, 2024

Nov 13, 2024

Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks

Nov 13, 2024

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times

Nov 13, 2024

Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

atai Life Sciences Advances Psychedelic Pipeline as FDA Clears DMT Depression Treatment | ATAI Stock News - StockTitan

Nov 13, 2024

Oct 21, 2024

374Water And 2 Other Promising US Penny Stocks To Watch - Simply Wall St

Oct 21, 2024

Oct 15, 2024

Are ATAI Life Sciences N.V.’shares a good deal? - US Post News

Oct 15, 2024

Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily

Oct 15, 2024

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan

Oct 15, 2024

Oct 11, 2024

Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily

Oct 11, 2024